Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine.
about
Patient Management with Eribulin in Metastatic Breast Cancer: A Clinical Practice GuideEribulin in the Management of Advanced Breast Cancer: Implications of Current Research FindingsEribulin in Cancer TreatmentNewer therapies for the treatment of metastatic breast cancer: a clinical updateBeyond taxanes: the next generation of microtubule-targeting agentsEribulin for the treatment of metastatic breast cancer: an update on its safety and efficacyEfficacy of eribulin in breast cancer: a short report on the emerging new data.Bevacizumab in Combination with Modified FOLFOX6 in Heavily Pretreated Patients with HER2/Neu-Negative Metastatic Breast Cancer: A Phase II Clinical Trial.Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer.Treatment options for patients with triple-negative breast cancerPhase 1 combination study of eribulin mesylate with trastuzumab for advanced or recurrent human epidermal growth factor receptor 2 positive breast cancer.Regression of brain metastases from breast cancer with eribulin: a case report.Eribulin mesylate as a microtubule inhibitor for treatment of patients with metastatic breast cancer.Eribulin mesylate (halichondrin B analog E7389) in platinum-resistant and platinum-sensitive ovarian cancer: a 2-cohort, phase 2 study.Brain Metastases from Breast Cancer and Response to Treatment with Eribulin: A Case SeriesEribulin mesylate in the treatment of metastatic breast cancerA phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California cancer consortium trial.Advances in the management of metastatic breast cancer: options beyond first-line chemotherapy.Eribulin-induced liver dysfunction as a prognostic indicator of survival of metastatic breast cancer patients: a retrospective studyImpact of prior anthracycline or taxane use on eribulin effectiveness as first-line treatment for metastatic breast cancer: results from two phase 2, multicenter, single-arm studiesA case of brain metastases from breast cancer treated with whole-brain radiotherapy and eribulin mesylate.Eribulin mesylate in patients with refractory cancers: a Phase I study.Eribulin monotherapy improved survivals in patients with ER-positive HER2-negative metastatic breast cancer in the real world: a single institutional review.Current approaches to the management of Her2-negative metastatic breast cancer.Eribulin in pretreated metastatic breast cancer patients: results of the TROTTER trial-a multicenter retrospective study of eribulin in real life.Chemotherapy in Patients with Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer: An Overview.CXCR4 Protein Epitope Mimetic Antagonist POL5551 Disrupts Metastasis and Enhances Chemotherapy Effect in Triple-Negative Breast Cancer.Eribulin for advanced breast cancer: a drug evaluation.Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who had well-defined taxane resistanceNovel therapies in breast cancer: what is new from ASCO 2008.Drug resistance and the role of combination chemotherapy in improving patient outcomes.Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy.Population pharmacokinetic-pharmacodynamic analysis for eribulin mesilate-associated neutropenia.Evolving approaches to metastatic breast cancer patients pre-treated with anthracycline and taxaneNovel combinations for the treatment of metastatic breast cancer.Eribulin (Halaven): a new, effective treatment for women with heavily pretreated metastatic breast cancer.Potential clinical applications of halichondrins in breast cancer and other neoplasms.Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for human epidermal growth factor receptor 2 positive locally recurrent or metastatic breast cancer: results from a Phase II, single-arm,Eribulin -- a review of preclinical and clinical studies.Eribulin drug review
P2860
Q26749476-80FB5E66-D4A3-4330-B42F-A7715B7784DBQ26774097-3DF71658-DDC7-424B-98C8-5F895D692BB2Q26799328-8F7261FE-1797-4CAA-BFA6-4FDE96461A6CQ26865260-8C507392-76B2-41DE-9C63-80DA776D684EQ26865369-96857D2A-D508-45B9-AC8E-42F18397FF84Q28088354-50FB848F-FEFF-4863-8477-E33F36D75657Q31167441-5B4CD0D5-0ABD-4E51-972E-950A3053789DQ33424566-FA7C1E6C-1B4E-423B-9100-131BC23E9543Q33858197-26E1E772-24D3-40AC-A1BA-0C12AF23D5F9Q34331406-DD1EB474-45EB-4C02-BC81-1A805E321297Q34964991-7738387F-E272-4DCC-BBA9-B7119EAD248BQ35071355-CC7BC45D-27E4-4816-91A3-B5309D0C2148Q35599745-3505E277-70DF-4EDD-86F0-CFB0A530738CQ35633159-0B87C350-FE58-45C3-9299-D129D80EC04BQ35647947-73C67E0B-B5FF-4E6F-ACFE-3B0B0BDB6B7EQ35699382-FEBD6EBA-43AD-41A3-A591-045B3448FE13Q35783841-D3417A5D-C467-4AAC-A690-13D0E855D45EQ35872691-F582DC80-2E4A-4C24-8471-CACD9DD04744Q36070349-DFD6D7AB-943D-475E-BFE5-E285D332FF15Q36079935-63B00E7C-1C0B-4307-A8A1-12376FE9F032Q36199963-BAF20B89-2960-4386-B7F2-117CB17F0B4FQ36205403-61C7EC58-AB85-4177-9B20-FFF603EF3AB9Q36234055-67A58D9F-3FED-40D7-BEC9-E18584F7E3DDQ36245461-E961BA73-3440-4381-8A52-B233222AB541Q36484243-0F5BB416-9CD0-422C-8F3D-AF929D70C0FBQ36630732-A0517D94-B89E-419F-A9C9-963F82A9CF5BQ36668951-C9B1BB97-0F99-4A72-A443-6AD827AF49B0Q36763961-0FC11E50-3690-4CB2-AF78-B8BF2DF62933Q36922483-C2F5994C-6524-4805-950D-3F8983C86DD5Q36964421-12BF4553-EA36-4AAF-9729-A3A22D4AE318Q36999509-5BF5ADF9-1750-49D0-9AE7-93965B6BDD04Q37067999-36B01A44-C4B3-4A21-AFCF-36A4C1A6077CQ37161899-499D05E1-250F-496D-8F3D-82F926D0E4FCQ37177111-6D423713-9999-46D9-BDB2-C218F9F184B9Q37307168-E07B3D63-C90B-484D-A1F7-E8DD8E5D8158Q37356090-9A305E5E-7F0D-4EEA-BE74-1713ECA5726EQ37356164-0EE3ABDF-7984-4970-8EF6-91B8642FFBC9Q37496378-007026C7-3246-43D5-8C31-661CF929A5CFQ37637936-A763D0D4-3921-4B02-9DCC-3C14DEE28A5DQ37654001-9F0FA85F-057A-45AA-A43B-4AFD189F7C95
P2860
Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 02 August 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Phase II study of the halichon ...... e, a taxane, and capecitabine.
@en
Phase II study of the halichon ...... e, a taxane, and capecitabine.
@en-gb
Phase II study of the halichon ...... e, a taxane, and capecitabine.
@nl
type
label
Phase II study of the halichon ...... e, a taxane, and capecitabine.
@en
Phase II study of the halichon ...... e, a taxane, and capecitabine.
@en-gb
Phase II study of the halichon ...... e, a taxane, and capecitabine.
@nl
prefLabel
Phase II study of the halichon ...... e, a taxane, and capecitabine.
@en
Phase II study of the halichon ...... e, a taxane, and capecitabine.
@en-gb
Phase II study of the halichon ...... e, a taxane, and capecitabine.
@nl
P2093
P356
P1476
Phase II study of the halichon ...... e, a taxane, and capecitabine.
@en
P2093
Ahmad Awada
Anthony Goncalves
Chris Twelves
Dale E Shuster
Elaine Richmond
Henri Roché
Jantien Wanders
Joanne L Blum
Linda Vahdat
P304
P356
10.1200/JCO.2009.25.8467
P407
P577
2010-08-02T00:00:00Z